Cas no 345909-35-5 (Kynurenic Acid Hydrate)

Kynurenic Acid Hydrate is a naturally occurring metabolite of the kynurenine pathway, known for its role as an endogenous antagonist of excitatory amino acid receptors, particularly NMDA and α7-nicotinic acetylcholine receptors. This compound exhibits neuroprotective properties by modulating glutamatergic neurotransmission and reducing excitotoxicity. Its hydrate form ensures improved solubility and stability for experimental applications. Kynurenic Acid Hydrate is widely utilized in neuroscience research to study neurodegenerative disorders, psychiatric conditions, and inflammatory processes. The product is characterized by high purity and consistent performance, making it suitable for in vitro and in vivo studies. Its ability to cross the blood-brain barrier further enhances its utility in pharmacological research.
Kynurenic Acid Hydrate structure
Kynurenic Acid Hydrate structure
Product Name:Kynurenic Acid Hydrate
CAS No:345909-35-5
MF:C10H9NO4
MW:207.182762861252
MDL:MFCD00149476
CID:92777
PubChem ID:18530299
Update Time:2025-10-18

Kynurenic Acid Hydrate Chemical and Physical Properties

Names and Identifiers

    • 4-Hydroxyquinoline-2-carboxylic acid
    • 4-Hydroxyquinoline-2-carboxylic acid hydrate
    • 4-HYDROXYQUINOLINE-2-CARBOXYLIC ACID, HYDRATE, 98
    • 2-Carboxy-4-hydroxyquinoline hydrate,4-Hydroxyquinaldic acid hydrate,Kynurenic acid hydrate
    • 4-Hydroxyquinoline-2-carboxylicacidhydrate
    • kynurenic acid monohydrate
    • BP-12465
    • SB70571
    • 4-Hydroxyquinoline-2-carboxylic acid,hydrate,98
    • VNA90935
    • MFCD00149476
    • 4-Hydroxyquinoline-2-carboxylic acid xhydrate
    • 4-oxo-1,4-dihydroquinoline-2-carboxylic acid hydrate
    • 4-oxo-1H-quinoline-2-carboxylic acid;hydrate
    • Kynurenic acid (hydrate)
    • AKOS024307448
    • 345909-35-5
    • 179637-97-9
    • SCHEMBL1421892
    • acid, kynurenic hydrate
    • Kynurenic Acid Hydrate
    • MDL: MFCD00149476
    • Inchi: 1S/C10H7NO3.H2O/c12-9-5-8(10(13)14)11-7-4-2-1-3-6(7)9;/h1-5H,(H,11,12)(H,13,14);1H2
    • InChI Key: WZQSVWRLXGIOBK-UHFFFAOYSA-N
    • SMILES: O=C1C=C(C(=O)O)NC2C=CC=CC=21.O
    • BRN: 147451

Computed Properties

  • Exact Mass: 207.05300
  • Monoisotopic Mass: 188.034768
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 1
  • Hydrogen Bond Acceptor Count: 4
  • Heavy Atom Count: 14
  • Rotatable Bond Count: 0
  • Complexity: 303
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 0
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Topological Polar Surface Area: 69.2

Experimental Properties

  • Color/Form: Not available
  • Melting Point: 275°C
  • Boiling Point: 358.4°Cat760mmHg
  • Flash Point: 170.5°C
  • Water Partition Coefficient: Soluble in hot ethanol and water. Insoluble in ether.
  • PSA: 79.65000
  • LogP: 1.57430
  • Merck: 14,5327
  • Solubility: Not available

Kynurenic Acid Hydrate Security Information

  • RTECS:VB2080000

Kynurenic Acid Hydrate Customs Data

  • HS CODE:29334910

Kynurenic Acid Hydrate Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
TRC
K660505-50mg
Kynurenic Acid Hydrate
345909-35-5
50mg
$64.00 2023-05-18
TRC
K660505-100mg
Kynurenic Acid Hydrate
345909-35-5
100mg
$75.00 2023-05-18
TRC
K660505-500mg
Kynurenic Acid Hydrate
345909-35-5
500mg
$87.00 2023-05-18
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.
ajci72278-1g
Kynurenic Acid (hydrate)
345909-35-5 98%
1g
¥437.00 2022-04-26
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.
ajci72278-5g
Kynurenic Acid (hydrate)
345909-35-5 98%
5g
¥1481.00 2022-04-26
WU HAN AN JIE KAI Biomedical Technology Co., Ltd.
ajci72278-500mg
Kynurenic Acid (hydrate)
345909-35-5 98%
500mg
¥286.00 2022-04-26
Apollo Scientific
OR12784-1g
4-Hydroxyquinoline-2-carboxylic acid hydrate
345909-35-5
1g
£16.00 2025-02-19
Apollo Scientific
OR12784-5g
4-Hydroxyquinoline-2-carboxylic acid hydrate
345909-35-5
5g
£47.00 2025-02-19
abcr
AB117327-5 g
4-Hydroxyquinoline-2-carboxylic acid hydrate, 98%; .
345909-35-5 98%
5 g
€111.20 2023-07-20
abcr
AB117327-25 g
4-Hydroxyquinoline-2-carboxylic acid hydrate, 98%; .
345909-35-5 98%
25 g
€354.00 2023-07-20

Kynurenic Acid Hydrate Related Literature

Additional information on Kynurenic Acid Hydrate

Kynurenic Acid Hydrate (CAS No: 345909-35-5) - A Comprehensive Overview

Kynurenic Acid Hydrate, chemically designated as C?H?NO?·xH?O, is a compound of significant interest in the field of biochemical research and pharmaceutical development. With a CAS number of 345909-35-5, this hydrated form of Kynurenic Acid has garnered attention due to its multifaceted roles in biological processes and its potential applications in therapeutic interventions.

The molecular structure of Kynurenic Acid Hydrate features a complex arrangement of atoms that contributes to its unique chemical properties. This compound is derived from the kynurenine pathway, a metabolic route that plays a crucial role in the degradation of tryptophan, an essential amino acid. The hydrated form indicates the presence of water molecules bound to the compound, which can influence its solubility and reactivity in various environments.

Recent advancements in biochemical research have highlighted the importance of Kynurenic Acid Hydrate in modulating neurological and inflammatory processes. Studies have demonstrated its potential as an antagonist at various ionotropic receptors, including the kainate receptor subtype GluR5. This receptor is involved in synaptic transmission and has been implicated in conditions such as epilepsy and neurodegenerative diseases. The ability of Kynurenic Acid Hydrate to interact with these receptors makes it a promising candidate for developing novel pharmacological agents.

In addition to its neurological effects, Kynurenic Acid Hydrate has been investigated for its anti-inflammatory properties. Research indicates that this compound can inhibit the production of pro-inflammatory cytokines, thereby potentially reducing inflammation in various pathological conditions. This mechanism has sparked interest in exploring its therapeutic potential in chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

The synthesis and characterization of Kynurenic Acid Hydrate have been subjects of extensive study. Researchers have developed efficient synthetic routes that yield high-purity forms of the compound, suitable for both laboratory research and potential clinical applications. Analytical techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, and X-ray crystallography have been employed to elucidate its molecular structure and confirm its identity.

One of the most intriguing aspects of Kynurenic Acid Hydrate is its role in the kynurenine pathway, which is also involved in the production of other bioactive molecules such as quinolinic acid and xanthurenic acid. These compounds have distinct biological functions and are implicated in various physiological and pathological processes. Understanding the interplay between these molecules within the kynurenine pathway is crucial for unraveling their collective roles in health and disease.

Current research is focused on exploring the therapeutic potential of Kynurenic Acid Hydrate in neurological disorders. Preclinical studies have shown that it can attenuate neuronal excitotoxicity, a key mechanism underlying damage in conditions like stroke and traumatic brain injury. Furthermore, its ability to modulate neurotransmitter systems makes it a candidate for treating neurodegenerative diseases such as Alzheimer's and Parkinson's disease.

The pharmacokinetic properties of Kynuretic Acid Hydrate are also under investigation to optimize its delivery and efficacy. Studies have examined its absorption, distribution, metabolism, and excretion (ADME) profiles to identify potential routes for administration that could enhance its therapeutic effects. These studies are crucial for translating preclinical findings into effective clinical treatments.

Industrial-scale production of Kynurenic Acid Hydrate is another area of focus, with researchers seeking cost-effective methods to produce high-quality material for research and pharmaceutical use. Biotechnological approaches, including enzymatic synthesis and fermentation processes, are being explored to improve yield and purity while reducing production costs.

The regulatory landscape for compounds like Kynurenic Acid Hydrate is evolving to accommodate new findings and applications. Regulatory agencies are increasingly recognizing the importance of such compounds in drug development and are establishing guidelines for their safe use in clinical trials. This evolving framework ensures that researchers can conduct studies with confidence while adhering to stringent safety standards.

In conclusion, Kynurenic Acid Hydrate (CAS No: 345909-35-5) represents a fascinating compound with diverse biological activities and therapeutic potential. Its role in modulating neurological and inflammatory processes underscores its importance as a target for drug development. As research continues to uncover new insights into its mechanisms of action, Kynurenic Acid Hydrate is poised to play a significant role in future medical treatments.

Recommended suppliers
Shaanxi pure crystal photoelectric technology co. LTD
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Shaanxi pure crystal photoelectric technology co. LTD
Enjia Trading Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Enjia Trading Co., Ltd
Inner Mongolia Xinhong Biological Technology Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Inner Mongolia Xinhong Biological Technology Co., Ltd
Zhengzhou Baoyu Pharmaceutical Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Zhengzhou Baoyu Pharmaceutical Co., Ltd.
Jiangsu Xinsu New Materials Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Jiangsu Xinsu New Materials Co., Ltd